These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37378639)

  • 21. (11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.
    Andersen VL; Hansen HD; Herth MM; Dyssegaard A; Knudsen GM; Kristensen JL
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1053-6. PubMed ID: 25655720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Nasrallah HA; Fedora R; Morton R
    Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin 5-HT
    García-Bea A; Miranda-Azpiazu P; Muguruza C; Marmolejo-Martinez-Artesero S; Diez-Alarcia R; Gabilondo AM; Callado LF; Morentin B; González-Maeso J; Meana JJ
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1453-1463. PubMed ID: 31734018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
    Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
    Price DL; Bonhaus DW; McFarland K
    Behav Pharmacol; 2012 Aug; 23(4):426-33. PubMed ID: 22750845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
    Abbas A; Roth BL
    Expert Opin Pharmacother; 2008 Dec; 9(18):3251-9. PubMed ID: 19040345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
    Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
    J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
    Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
    J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Selective" serotonin 5-HT
    Casey AB; Cui M; Booth RG; Canal CE
    Biochem Pharmacol; 2022 Jun; 200():115028. PubMed ID: 35381208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relevance of 5-HT
    Burstein ES
    CNS Drugs; 2021 Jul; 35(7):727-741. PubMed ID: 34224112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
    Jalal B
    Psychopharmacology (Berl); 2018 Nov; 235(11):3083-3091. PubMed ID: 30288594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
    Hermanowicz S; Hermanowicz N
    Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
    Rojas M; Chávez-Castillo M; Duran P; Ortega Á; Bautista-Sandoval MJ; Salazar J; Riaño-Garzón M; Chacín M; Medina-Ortiz O; Palmar J; Cudris-Torres L; Bermúdez V
    Curr Pharm Des; 2022; 28(33):2725-2741. PubMed ID: 36321314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.
    Banks ML
    Drug Alcohol Depend; 2016 Aug; 165():260-4. PubMed ID: 27242287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological Mechanism of the Non-hallucinogenic 5-HT
    Cunningham MJ; Bock HA; Serrano IC; Bechand B; Vidyadhara DJ; Bonniwell EM; Lankri D; Duggan P; Nazarova AL; Cao AB; Calkins MM; Khirsariya P; Hwu C; Katritch V; Chandra SS; McCorvy JD; Sames D
    ACS Chem Neurosci; 2023 Jan; 14(1):119-135. PubMed ID: 36521179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.